A new study published in the Journal of the American Medical Association found that administration of anti–vascular ...

D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage devel ...

LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked ...

Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc.

Key market opportunities for Lucentis include its broad approval for multiple retinal diseases, its proven clinical efficacy, and strong physician trust. Despite competition, its established global ...

Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a ...

A treatment that targets dysfunctional photoreceptors regardless of the underlying genetic mutation leads to improved ...

Incretin-PRINTed rodents, whether maintained on standard chow or a high-fat diet, demonstrated that sustained GLP-1 receptor agonist exposure correlated with favorable PD effects, including reductions ...

A Daniel, Wyoming man who narrowly averted a fire in his home last week after a lithium-ion battery spontaneously ...

Growing at a rapid pace, Apex Eyecare is poised to hire a second optometrist and a nurse practitioner in the coming months, ...

EyePoint Pharmaceuticals’ latest earnings call painted a picture of a company racing ahead clinically while absorbing heavy financial strain. Management struck an optimistic tone around late‑stage ...

Resolution occurred after stopping dulaglutide, no obvious clues to mechanism ...